HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice

Cancer Gene Therapy

Volumn 19, Issue 12, 2012, Pages 888-898

  MacLeod, S H ^a   Elgadi, M M ^b,c   Bossi, G ^b,d   Sankar, U ^b   Pisio, A ^a   Agopsowicz, K ^a   Sharon, D ^a   Graham, F L ^b   Hitt, M M ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

adenovirus; breast cancer; HER3 4; heregulin; tropism

Indexed keywords

ADENOVIRUS VECTOR; HEREGULIN ALPHA; NEU DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE INSERTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRION; VIRUS PARTICLE; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BREAST NEOPLASMS; CRICETINAE; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; INJECTIONS, INTRALESIONAL; MICE; RECEPTOR, ERBB-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; CRICETULUS GRISEUS; MUS;

EID: 84869206579     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.79     Document Type: Article

References (93)

1. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008; 25: 462-466.
2. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027. (Pubitemid 41324561)
3. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-148. (Pubitemid 46348628)
4. Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res 2000; 55: 479-505.
5. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 1997; 40: 137-206.
6. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6(Suppl 1): S152-S163. (Pubitemid 40228024)
7. Louis N, Fender P, Barge A, Kitts P, Chroboczek J. Cell-binding domain of adenovirus serotype 2 fiber. J Virol 1994; 68: 4104-4106. (Pubitemid 24177446)
8. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323. (Pubitemid 27114163)
9. Bergelson JM. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol 1999; 57: 975-979. (Pubitemid 29168545)
10. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356. (Pubitemid 27157315)
11. Law LK, Davidson BL. What does it take to bind CAR? Mol Ther 2005; 12: 599-609. (Pubitemid 41350141)
12. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319. (Pubitemid 23123309)
13. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 promotes adenovirus mediated cell membrane premeablilization. J Cell Biol 1994; 127: 257-264.
14. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base abolish its cell-rounding activity and delay virus production in flat cells. J Virol 1993; 67: 5198-5205. (Pubitemid 23241350)
15. Bai M, Campisi L, Freimuth P. Vitronectin receptor antibodies inhibit infection of HeLa and A549 cells by adenovirus type 12 but not by adenovirus type 2. J Virol 1994; 68: 5925-5932. (Pubitemid 24258610)
16. Coyne CB, Bergelson JM. CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 2005; 57: 869-882. (Pubitemid 40488108)
17. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M et al. Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy 1999; 6: 1520-1535. (Pubitemid 29465510)
18. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-5748. (Pubitemid 29006415)
19. Li D, Duan L, Freimuth P, O'Malley Jr BW. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999; 5: 4175-4181. (Pubitemid 30013802)
20. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al. Loss of adenovirus receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-330. (Pubitemid 29048862)
21. Hemmi Y, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirusmediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363-2373. (Pubitemid 28523985)
22. Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002; 62: 4273-4281. (Pubitemid 34827282)
23. Pandha HS, Stockwin LH, Eaton J, Clarke IA, Dalgleish AG, Todryk SM et al. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 2003; 6: 6-11. (Pubitemid 36432614)
24. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenovirus vectors. Mol Ther 2000; 1: 391-405.
25. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007; 7: 189-204. (Pubitemid 46902201)
26. Devaux C, Adrian M, Berthet-Colominas C, Cusacks S, Jacrot B. Structure of adenovirus fiber. I. Analysis of crystals of fiber from adenovirus serotypoes 2 and 5 by electron microscopy and X-ray crystalography. J Mol Biol 1990; 215: 567-588. (Pubitemid 20361393)
27. Novelli A, Boulanger PA. Deletion analysis of functional domains in baculovirusexpressed adenovirus type 2 fiber. Virology 1991; 185: 365-376.
28. Xia D, Henry LJ, Gerard RD, Deisenhofer J. Crystal structure of the receptorbinding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994; 2: 1259-1270. (Pubitemid 124001323)
29. van Raaij MJ, Mitraki A, Lavigne G, Cusack S. A triple b-spiral in the adenovirus fiber shaft reveals a new structural motif for a fibrous protein. Nature 1999; 401: 935-938.
30. Henry LJ, Xia D, Wilke ME, Deisenhofer J, Gerard RD. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol 1994; 68: 5239-5246. (Pubitemid 24226593)
31. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844-1852. (Pubitemid 28100735)
32. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713. (Pubitemid 28520834)
33. Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow GR et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542. (Pubitemid 34026868)
34. Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol 1999; 73: 9130-9136. (Pubitemid 29487066)
35. Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J et al. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 2009; 16: 256-265.
36. Kurachi S, Tashiro K, Sakurai F, Sakurai H, Kawabata K, Yayama K et al. Fibermodified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity. Gene Therapy 2007; 14: 1160-1165. (Pubitemid 47086746)
37. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621-8631. (Pubitemid 34864056)
38. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW et al. Identification of heregulin, a specific activator of p185erbB2. Science 1992; 256: 1205-1210.
39. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG et al. Isolation of neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992; 69: 205-216.
40. Kita Y, Mayer J, Zamborelli T, Hara S, Rohde M, Watson E et al. Bioactive synthetic peptide of NDF/heregulin. Biochem Biophys Res Commun 1995; 210: 441-451.
41. Singer E, Landgraf R, Horan T, Slamon D, Eisenberg D. Identification of a heregulin binding site in HER3 extracellular domain. J Biol Chem 2001; 276: 44266-44274.
42. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269: 14661-14665.
43. Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993; 366: 473-475. (Pubitemid 24013882)
44. Carraway 3rd KL, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994; 78: 5-8.
45. Carraway III KL, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A et al. The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994; 269: 14303-14306. (Pubitemid 24191194)
46. Kita YA, Barff J, Luo Y, Wen D, Brankow D, Hu S et al. NDF/heregulin stimulates the phosphorylation of Her3/erbB3. FEBS Lett 1994; 349: 139-143. (Pubitemid 24230238)
47. Barbacci EG, Guarino BC, Stroh JG, Singleton DH, Rosnack KJ, Moyer JD et al. The structural basis for the specificity of epidermal growth factor and heregulin binding. J Biol Chem 1995; 270: 9585-9589.
48. Jacobsen NE, Abadi N, Sliwkowski MX, Reilly D, Skelton NJ, Fairbrother WJ. High-resolution solution structure of the EGF-like domain of heregulin-alpha. Biochemistry 1996; 35: 3402-3417. (Pubitemid 26092562)
49. Nagata K, Kohda D, Hatanaka H, Ichikawa S, Matsuda S, Yamamoto T et al. Solution structure of the epidermal growth factor-like domain of heregulin-alpha, a ligand for p180erbB-4. EMBO J 1994; 13: 3517-3523.
50. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 1992; 66: 1116-1121. (Pubitemid 23006153)
51. Gullick WJ. The c-erbB3/HER3 receptor in human cancer. Cancer Surv 1996; 27: 339-349. (Pubitemid 26363837)
52. Holbro T, Civenni G, Hynes NE. The erbB receptors and thier role in cancer progression. Exp Cell Res 2003; 284: 99-110. (Pubitemid 36331969)
53. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008; 15: 413-448. (Pubitemid 351822188)
54. Uberall I, Kolar Z, Trojanec R, Berkovcova J, Hajduch M. The status and role of ErbB receptors in human cancer. Exp Mol Pathol 2008; 84: 79-89.
55. Han X, Kasahara N, Wai Kan Y. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995; 92: 9747-9751.
56. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
57. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
58. Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet 1996; 22: 477-488. (Pubitemid 27194364)
59. Stemmer WPC, Crameri A, Ha KD, Brennan TM, Heyneker HL. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 1995; 164: 49-53.
60. Hitt MM, Ng P, GF. L. Construction and propagation of human adenovirus vectors. In: Celis JE (ed.) Cell Biology: A Laboratory Handbook. 3rd edn. vol. 1. Academic Press: San Diego, CA, 2006, pp 435-443.
61. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570. (Pubitemid 26424159)
62. Maizel JV, White D, Scharff MD. The polypeptides of adenovirus. I. Evidence of multiple protein components in the virion and a comparison of types 2, 7a, and 12. Virology 1968; 36: 115-125.
63. Falcone D, Andrews DW. Both the 50 untranslated region and the sequence surrounding the start site contribute to efficient initiation of translation in vitro. Mol Cell Biol 1991; 11: 2656-2664. (Pubitemid 21895645)
64. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
65. Graham FL. Covalently closed circles of human adenovirus DNA are infectious. EMBO J 1984; 3: 2917-2922.
66. Ng P, Parks RJ, Cummings DT, Evelegh CM, Graham FL. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther 2000; 11: 693-699. (Pubitemid 30180274)
67. Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000; 74: 6875-6884. (Pubitemid 30470671)
68. Kashentseva EA, Seki T, Curiel DT, Dmitriev IP. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 2002; 62: 609-616. (Pubitemid 34106439)
69. Li Y, Yao XM, Hong-Brown L, Massa SM. Adaptable modification of adenoviral tropism using a bifunctional ligand protein. Virus Res 2003; 91: 223-230. (Pubitemid 36165091)
70. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70: 6831-6838. (Pubitemid 26307394)
71. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002; 76: 6893-6899. (Pubitemid 41246204)
72. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8: 730-735. (Pubitemid 32496435)
73. Xia H, Anderson B, Mao Q, Davidson BL. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000; 74: 11359-11366. (Pubitemid 32224006)
74. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999; 73: 5156-5161. (Pubitemid 29246779)
75. Wickham TJ, Tzeng E, Shears II LL, Roelvink PW, Li Y, Lee GM et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229. (Pubitemid 27446397)
76. Zakhartchouk A, Connors W, van Kessel A, Tikoo SK. Bovine adenovirus type 3 containing heterologous protein in the C-terminus of minor capsid protein IX. Virology 2004; 320: 291-300. (Pubitemid 38315155)
77. Poulin KL, Lanthier RM, Smith AC, Christou C, Risco Quiroz M, Powell KL et al. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 84: 10074-10086.
78. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparancontaining receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14: 1570-1573. (Pubitemid 26365551)
79. Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, Barry MA. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther 2003; 8: 688-700. (Pubitemid 37321698)
80. Charles YC, Patricia M, Glen RN, Phoebe LS. Structure of adenovirus complexed with its internalization receptor, v5 integrin. J Virol 1999; 73: 6759-6768.
81. Stewart PL, Chiu CY, Huang S, Muir T, Zhao Y, Chait B et al. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J 1997; 16: 1189-1198. (Pubitemid 27136086)
82. Landgraf R, Pegram M, Slamon DJ, Eisenberg D. Cytotoxicity and specificity of directed toxins composed of dephtheria toxin and the EGF-like domain of heregulin b1. Biochemistry 1998; 37: 3220-3228.
83. Leguchi K, Fujita M, Ma Z, Davari P, Taniguchi Y, Sekiguchi K et al. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling. J Biol Chem 2010; 285: 31388-31398.
84. Landgraf R, Eisenberg D. Heregulin reverses the oligomerization of HER3. Biochemistry 2000; 39: 8503-8511. (Pubitemid 30489947)
85. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9: 1769-1774. (Pubitemid 28418747)
86. Steffensen KD, Waldstrom M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ et al. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol 2008; 33: 195-204.
87. Matthews KS, Alvarez RD, Curiel DT. Advancements in adenoviral based virotherapy for ovarian cancer. Adv Drug Deliv Rev 2009; 61: 836-841.
88. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 2001; 1: 525-538. (Pubitemid 33768667)
89. Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A et al. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 2008; 108: 166-172. (Pubitemid 350299441)
90. Rein DT, Volkmer A, Beyer IM, Curiel DT, Janni W, Dragoi A et al. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus. Gynecol Oncol 2011; 123: 138-146.
91. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Fut Oncol 2006; 2: 137-143.
92. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
93. Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, Hayakawa T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR-and alphav integrin-binding ablation. J Virol 2003; 77: 13062-13072. (Pubitemid 37494302)